leish-111f + mpl-se

Vaccineexperimental

Clinical trial activity

5 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2004 (NCT00111514)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • leish-111f + mpl-se
  • leish-111f + mpl-se v

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00486382Phase 1Apr 1, 2007Banaras Hindu University, Bill and Melinda Gates Foundation, Immune Design, Infectious Disease Research Institute
NCT00121849Phase 1Aug 1, 2005Bill and Melinda Gates Foundation, Infectious Disease Research Institute, PECET, Medellin, Colombia
NCT00121862Phase 2Aug 1, 2005Bill and Melinda Gates Foundation, Immune Design, Infectious Disease Research Institute
NCT00111553Phase 1Oct 1, 2004Bill and Melinda Gates Foundation, Federal University of Minas Gerais, Infectious Disease Research Institute
NCT00111514Phase 1Jul 1, 2004Bill and Melinda Gates Foundation, Cayetano Heredia University, Immune Design, Infectious Disease Research Institute
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bill and Melinda Gates FoundationAcademic/Hospital5022004
Infectious Disease Research InstituteAcademic/Hospital5522004
Immune DesignFor profit3022004
Banaras Hindu UniversityAcademic/Hospital1012007
Cayetano Heredia UniversityAcademic/Hospital1012004
Federal University of Minas GeraisAcademic/Hospital1012004
PECET, Medellin, ColombiaAcademic/Hospital1012005
7 organizations
Page 1 / 1